References
- NORD. Rare disease information. Available at: http://www.rarediseases.org/rare-disease-information [Last accessed 15 November 2011]
- Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009;96:20-6
- Taruscio D, Capozzoli F, Frank C. Rare diseases and orphan drugs. Ann Ist Super Sanita 2011;47:83-93
- EURORDIS. Rare Diseases: Understanding This Public Health Priority. Available at: http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf [Last accessed 2 December 2011]
- Eurodis, Orphanet. Rare disease in numbers: preliminary report from an on going bibliographic study initiated by Eurordis in partnership with Orphanet. Available at: http://ec.europa.eu/health/archive/ph_threats/non_com/docs/rdnumbers.pdf [Last accessed 15 November 2011]
- Cheng MM, Ramsey SD, Devine EB, et al. Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care 2012;18:47-62
- Garrison LP Jr, Neumann PJ, Radensky P, et al. A flexible approach to evidentiary standards for comparative effectiveness research. Health Aff (Millwood) 2010;29:1812-17
- Dorsey ER, de Roulet J, Thompson JP, et al. Funding of US biomedical research, 2003–2008. JAMA 2010;303:137-43
- Braun MM, Farag-El-Massah S, Xu K, et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov 2010;9:519-22
- Holtzclaw Williams P. Policy framework for rare disease health disparities. Policy Polit Nurs Pract 2010;12:114-18
- Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy 2009;95:216-28
- Dunkle M, Pines W, Saltonstall PL. Advocacy groups and their role in rare diseases research. Adv Exp Med Biol 2010;686:515-25
- Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2011;9:921-9
- Rubinstein YR, Groft SC, Bartek R, et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials 2010;31:394-404
- Takemoto SK, Arns W, Bunnapradist S, et al. Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation 2008;86:18-25
- Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 2007;10:326-35
- Sun P, Kohrman M, Liu Z, et al. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis. Curr Med Res Opin 2012;28(4)
- Sun P, Krueger D, Liu Z, et al. Surgical resection of subependymal giant cell astrocytomas (SEGA) and changes in SEGA-related conditions: a US national claims database study. Curr Med Res Opin 2012;28(4)